The bioXclusters plus internationalization project is the continuation of the bioXclusters alliance, in which Biocat participated from 2012 to 2014. This new program, developed with the support of the European Union, aims to become the most competitive meta-cluster in Europe, capable of addressing health-related challenges and promoting the growth of SMEs in the sector, with particular emphasis on personalized medicine as a tool for responding to the future of global health over the next few years.
More information and latest news: bioxclusters.eu
Improving the international position, strengthening relationships with already explored markets (USA, China and Brazil), opening new markets (Japan, Australia and others), providing customized tools for promoting the internationalization of companies, identifying areas of technological exchange and collaboration with other bioregions are the main areas of action that bioXclusters plus is involved in.
In this second phase the alliance focuses on regenerative therapies, digital health and nutrition. It also seeks to establish collaboration among other European healthcare clusters in order to promote know-how, technological transfer and cross fertilization with other technological sectors (ICT, microsystems, nanotechnology, new materials, etc.) to help achieve state-of-the-art solutions in personalized medicine.
bioXclusters plus receives funds from the European program Competitiveness of Enterprises and Small and Medium-sized Enterprises (COSME). The alliance represents 3,300 European SMEs operating in the area of personalized healthcare. It also represents 200 large companies in the biotechnology and pharmaceutical sectors. It brings together 23,000 researchers in the public sector and more than 358,000 job positions in both the private and public sectors.
Among the first actions to be carried out as part of the bioXclusters plus project is the business mission to Japan, which will take place in October 2016. The aim of the mission is to explore business opportunities in the Japanese market, which represents the second-largest pharmaceutical market in the world and leads the sector in imports.